Table 2.

Correlation between clinicopathological features and expression levels of lncRNA in plasma with gastric adenocarcinoma.

Characteristic	Case	lnc-MB21D1-3:5		lnc-PSCA-4:2		lnc-ABCC5-2:1
		Median (range), △CT	p-vaule	Median (range), △CT	p-vaule	Median (range), △CT	p-vaule
Gender
Male	36	2.62 (0.98-3.84)	0.488	6.36 (4.27-7.35)	0.751	6.07 (9.32-0.23)	0.960
female	16	2.36 (1.62-5.56)		6.35 (4.10-9.06)		6.45 (0.47-9.93)
Age (years)
≤65	26	2.43 (0.98-2.84)	0.840	6.52 (4.10-7.49)	0.227	6.44 (0.32-9.63)	0.370
>65	26	2.45 (1.14-5.65)		6.05 (4.27-9.06)		5.86 (0.47-9.93)
Tumor size (cm)
<5	25	2.59 (0.98-5.65)	0.985	6.36 (4.58-9.06)	0.356	6.45 (0.32-8.87)	0.679
≥5	27	2.36 (1.14-3.62)		6.23 (4.58-9.06)		5.74 (0.47-9.93)
Differentiation
Moderate/well	18	2.20 (1.14-3.62)	0.018	6.42 (4.10-9.06)	0.768	6.07 (1.74-9.93)	0.904
Poor	29	2.63 (0.98-5.62)		6.34 (4.58-7.49)		6.38 (0.32-9.23)
TNM stage
I, II	20	2.60 (0.98-5.65)	0.463	6.77 (4.29-9.06)	0.025	5.69 (0.32-8.87)	0.259
III, IV	32	2.36 (1.14-3.31)		6.13 (4.10-7.14)		6.27 (1.74-9.93)
Lymph node metastasis
Negative	14	2.66 (0.98-5.65)	0.004	6.88 (5.43-9.06)	0.025	5.12 (0.32-8.05)	0.259
Positive	38	2.36 (1.14-3.31)		6.13 (4.10-7.27)		6.38 (1.74-9.93)
Nerve invasion
Yes	29	2.44 (1.44-5.65)	0.706	6.22 (4.10-7.14)	0.077	6.38 (3.12-9.93)	0.176
No	23	2.46 (0.98-3.84)		6.55 (4.27-9.06)		5.14 (0.32-8.87)
Vessel invasion
Yes	34	2.47 (1.14-5.655)	0.729	6.13 (4.10-7.49)	0.036	6.31 (1.74-9.93)	0.281
No	18	2.45 (0.98-3.84)		6.60 (4.27-9.06)		5.12 (0.32-9.23)

The bold values highlight statistical significance.